{"pub": "investing.com", "url": "https://ph.investing.com/news/forex-news/newsbreak-astrazenecas-diabetes--drug-farxiga-gets-us-approval-69559", "downloaded_at": "2019-10-21 06:44:12.198908+00:00", "title": "NewsBreak: Astrazeneca's Diabetes Drug Farxiga Gets U.S. Approval By Investing.com", "language": "en", "text": "NewsBreak: Astrazeneca's Diabetes Drug Farxiga Gets U.S. Approval\n\nForex 10 minutes ago (Oct 21, 2019 14:34)\n\n\u00a9 Reuters. Investing.com -- AstraZeneca (LON: ) said Monday its Farxiga drug for reducing the risk of heart failure in type-2 diabetes patients had been approved for use in the U.S. by the Food and Drug Administration. The drug is the first inhibitor of its type to be authorized in the world's largest health market, BioPharmaceuticals Business Unit head Ruud Dobber said in a press release. There are an estimated 30 million people living with type-2 diabetes in the US, and heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke. AstraZeneca shares are up 15% so far this year\n\nNewsBreak: Astrazeneca's Diabetes Drug Farxiga Gets U.S. Approval", "description": "NewsBreak: Astrazeneca's Diabetes  Drug Farxiga Gets U.S. Approval", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXMPEA6O0R6_L.jpg", "published_at": "2019-10-21"}